Grundlæggende statistik
| CIK | 1566049 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Alcobra Ltd.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 16, 2019 |
ARCT / Arcturus Therapeutics Ltd. CORRESP - - CORRESP Jeffrey A. Baumel Partner [email protected] D +1 973 912 7189 Dentons US LLP 1221 Avenue of the Americas New York, NY 10020-1089 USA August 16, 2019 VIA EDGAR Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-1090 Attention: Andi Carpenter Re: Arcturus Therapeutics Ltd. Form 10-K for the Fiscal |
|
| August 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 1, 2019 |
EX-99.1 2 e618580ex99-1.htm Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients San Diego, Calif, August 1, 2019 - Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis Foundation (CF Foundation), has increased its commitmen |
|
| June 21, 2019 |
2019 Omnibus Equity Incentive Plan EX-4.7 Exhibit 4.7 ARCTURUS THERAPEUTICS HOLDINGS INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN (Effective June 10, 2019) TABLE OF CONTENTS PAGE Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 2 2.4 “Board” 2 2.5 “Bonus Shares” 2 2.6 |
|
| June 21, 2019 |
ARCT / Arcturus Therapeutics Ltd. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on June 21, 2019 Registration No. |
|
| June 20, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| June 20, 2019 |
EX-99.1 5 d721252dex991.htm EX-99.1 Exhibit 99.1 Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases • Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics • $30 million of upf |
|
| June 20, 2019 |
EX-10.1 Exhibit 10.1 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is made as of June 18, 2019, by and among Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Investor”), Arcturus Therapeutics Ltd., an Israeli incorporated company (“Arcturus-Israel”), and Arcturus Therapeutics Holdings Inc., a newly incorporated Delaware corporation (“Arcturus-Delaware”). W |
|
| June 20, 2019 |
EX-10.2 Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 THIRD AMENDMENT TO RESEARCH COLLABORATION AND LICENSE AGREEMENT This THIRD AMENDMENT TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Third Amendment”) is effective as of June 18, 2019 (“Third Amendment Eff |
|
| June 20, 2019 |
EX-4.1 Exhibit 4.1 CONFIDENTIAL REGISTRATION RIGHTS AGREEMENT by and between ARCTURUS THERAPEUTICS HOLDINGS INC. and ULTRAGENYX PHARMACEUTICAL INC. Dated as of June 18, 2019 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 18, 2019, is by and between Arcturus Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and Ultragenyx Phar |
|
| May 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2019 ARCTURUS THERAPEUTICS LTD. |
|
| May 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2019 ARCTURUS THERAPEUTICS LTD. |
|
| May 13, 2019 |
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update EX-99.1 2 arct-ex9916.htm EX-99.1 Exhibit 99.1 Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update San Diego, Calif, May 13, 2019 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today reported its financial results for the |
|
| May 13, 2019 |
ARCT / Arcturus Therapeutics Ltd. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35932 ARCTURUS THERAPEUTICS LTD. |
|
| April 12, 2019 |
PROXY STATEMENT OF ARCTURUS THERAPEUTICS LTD. PROSPECTUS OF ARCTURUS THERAPEUTICS HOLDINGS INC. 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No.: 333-230353 PROXY STATEMENT OF ARCTURUS THERAPEUTICS LTD. PROSPECTUS OF ARCTURUS THERAPEUTICS HOLDINGS INC. Dear Shareholders of Arcturus Therapeutics Ltd.: We are making this proxy statement/prospectus available in connection with the solicitation by the board of directors of Arcturus Therapeutics Ltd. (“Arcturus-Israel” or |
|
| April 11, 2019 |
ARCT / Arcturus Therapeutics Ltd. S-4/A S-4/A Table of Contents As filed with the Securities and Exchange Commission on April 11, 2019 Registration No. |
|
| April 11, 2019 |
ARCT / Arcturus Therapeutics Ltd. CORRESP - - CORRESP ARCTURUS THERAPEUTICS LTD. ARCTURUS THERAPEUTICS HOLDINGS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 250 SAN DIEGO, CA 92121 April 11, 2019 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Arcturus Therapeutics Ltd. Arcturus Therapeutics Holdings, Inc. Registration Statement on Form S-4 File No. 333-230353 Ladies and Gentlem |
|
| April 10, 2019 |
EX-10.14 2 arct-ex10146.htm EX-10.14 EXHIBIT 10.14 AMENDED AND RESTATED Joint venture, research COLLABORATION AND LICENSE AGREEMENT This Amended and Restated Joint Venture, Research Collaboration And License Agreement (this “Agreement”) is entered into as of July , 2018 (the “Restatement Date”), by and between Providence Therapeutics Inc., a corporation incorporated under the laws of Alberta, Cana |
|
| April 10, 2019 |
ARCT / Arcturus Therapeutics Ltd. 10-K/A (Annual Report) 10-K/A 1 arct-10ka20181231.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commissi |
|
| March 18, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 arct-8k20190318.htm ARCT 8-K - Q4 2018 PR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2019 ARCTURUS THERAPEUTICS LTD. (Exact Name of Registrant as Specified in Charter) State of Israel (State or Other Jurisdiction |
|
| March 18, 2019 |
Exhibit 99.1 Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results San Diego, Calif, March 18, 2019 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today reported its financial results for the quarter and |
|
| March 18, 2019 |
EX-10.15 4 arct-ex1015582.htm EX-10.15 Exhibit 10.15 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 RESEARCH COLLABORATION AGREEMENT This Research Collaboration Agreement is entered into and effective as of March 8, 2019 (the “Effective Date”), by and between Arcturus Therapeuti |
|
| March 18, 2019 |
Exhibit 10.14 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 AMENDED AND RESTATED Joint venture, research COLLABORATION AND LICENSE AGREEMENT This Amended and Restated Joint Venture, Research Collaboration And License Agreement (this “Agreement”) is entered into as of July , 201 |
|
| March 18, 2019 |
Exhibit 14.1 Code of Business Conduct and Ethics Introduction Ethics are important to Arcturus Therapeutics Ltd. (together with its subsidiaries, “Arcturus”) and its directors, officers and employees (each an “Associate”). Arcturus is committed to the highest ethical standards and to conducting its business with the highest level of integrity. The Arcturus Code of Business Conduct and Ethics (the |
|
| March 18, 2019 |
Exhibit 10.13 AGREEMENT drawn up and signed on February 8, 2019 between: ARCTURUS THERAPEUTICS LTD. Company number 514098995 of 58 Harakevet Street Tel-Aviv, Israel (the “Israeli Company”) of the first part; and: ARCTURUS THERAPEUTICS HOLDINGS INC. of 251 Little Falls Drive New Castle County The State of Delaware, 19808 United States (the “New Company”) of the second part; Whereas the Israeli Comp |
|
| March 18, 2019 |
ARCT / Arcturus Therapeutics Ltd. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-35932 ARCTURUS THERAP |
|
| March 16, 2019 |
S-4 Table of Contents As filed with the Securities and Exchange Commission on March 18, 2019 Registration No. |
|
| February 27, 2019 |
Presentation of Arcturus Therapeutics Ltd., dated February 2019 |
|
| February 27, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 27, 2019 ARCTURUS THERAPEUTICS LTD. |
|
| February 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Arcturus Therapeutics Ltd (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) |
|
| February 14, 2019 |
ARCT / Arcturus Therapeutics Ltd. / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 11, 2019 |
EX-99.2 3 e618214ex99-2.htm Exhibit 99.2 Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency San Diego, CA – Feb. 11, 2019 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today |
|
| February 11, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 8, 2019 ARCTURUS THERAPEUTICS LTD. |
|
| February 11, 2019 |
Presentation of Arcturus Therapeutics Ltd., dated February 11, 2019 |
|
| January 25, 2019 |
ARCT / Arcturus Therapeutics Ltd. / FRANKLIN RESOURCES INC Passive Investment arct18a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. M2239P109 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARCTURUS THERAPEUTICS LTD. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M2239P109 (CUSIP Number) December 31, 2018 (Da |
|
| November 20, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) Jeffrey Baum |
|
| November 7, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 arct6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2018 Commission File Number: 001-35932 ARCTURUS THERAPEUTICS LTD. (Exact Name of Registrant as Specified in Its Charter) 10628 Science Center Drive, Suite |
|
| November 7, 2018 |
Exhibit 99.2 ARCTURUS THERAPEUTICS LTD. AND ITS SUBSIDIARIES MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Ltd. for the three and nine-month periods ended September 30, 2018. Unless otherwise specified herein, references to the “Company,” “we,” “us” or |
|
| November 7, 2018 |
ARCTURUS THERAPEUTICS LTD. AND ITS SUBSIDIARIES TABLE OF CONTENTS EX-99 2 arctex991.htm EX-99.1 Exhibit 99.1 ARCTURUS THERAPEUTICS LTD. AND ITS SUBSIDIARIES TABLE OF CONTENTS Page Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2018 (Unaudited) and December 31, 2017 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017 (Unaudited) 2 Condensed Conso |
|
| November 7, 2018 |
Exhibit 99.3 Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results San Diego, Calif, November 7, 2018 (GLOBE NEWSWIRE) – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need |
|
| October 15, 2018 |
As filed with the Securities and Exchange Commission on October 15, 2018 Registration No. |
|
| October 15, 2018 |
Exhibit 10.2 Arcturus Therapeutics Ltd. Ordinary Shares (NIS 0.07 par value) SALES AGREEMENT October 15, 2018 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th New York, New York 10019 Ladies and Gentlemen: Arcturus Therapeutics Ltd., an Israeli company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1.Issuance and Sale of Shares |
|
| October 15, 2018 |
EXHIBIT 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 ARCTURUS THERAPEUTICS, INC., a DELAWARE CORPORATION WESTERN ALLIANCE BANK, an arizona corporation LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of October 12, 2018 by |
|
| October 15, 2018 |
ADHD / Alcobra Ltd. ARCT 6-K 2018-10-15 (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2018 (Report No. 2) Commission File Number: 001-35932 ARCTURUS THERAPEUTICS LTD. (Exact Name of Registrant as Specified in Its Charter) 10628 Science Center Drive, Suite 250 San Die |
|
| October 15, 2018 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-209960 PROSPECTUS SUPPLEMENT (To Prospectus dated March 1, 2016) Up to $30,000,000 Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink, dated October 15, 2018, relating to our ordinary shares, par value NIS 0.07 per share, offered by this prospectus supplement and the accompanyin |
|
| October 1, 2018 |
Exhibit 99.1 Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update San Diego, Calif, October 1, 2018 (GLOBE NEWSWIRE) – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need |
|
| October 1, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) 6-K 1 arct-6k20181001.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2018 Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Di |
|
| October 1, 2018 |
RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENT EX-99.2 3 arct-ex9926.htm EX-99.2 EXHIBIT 99.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENT THIS RESTATED AMENDMENT TO DEVELOPMENT AND OPTION AGREEMENT (this “Amendment”), dated as of September 28, 2018 (the “Amendment Res |
|
| September 28, 2018 |
EX-99 3 arct-ex992.htm EX-99.2 Exhibit 99.2 ARCTURUS THERAPEUTICS LTD. AND ITS SUBSIDIARIES MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Ltd. for the three and six-month periods ended June 30, 2018. Unless otherwise specified herein, references to the |
|
| September 28, 2018 |
ARCTURUS THERAPEUTICS LTD. AND ITS SUBSIDIARIES TABLE OF CONTENTS EX-99 2 arct-ex991.htm EX-99.1 Exhibit 99.1 ARCTURUS THERAPEUTICS LTD. AND ITS SUBSIDIARIES TABLE OF CONTENTS Page Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2018 (Unaudited) and December 31, 2017 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2018 and 2017 (Unaudited) 2 Condensed Consolidated St |
|
| September 28, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2018 Commission File Number: 001-35932 ARCTURUS THERAPEUTICS LTD. (Exact Name of Registrant as Specified in Its Charter) 10628 Science Center Drive, Suite 250 San Diego, Californi |
|
| August 29, 2018 |
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer EX-99.3 4 e618248ex99-3.htm Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer San Diego, Calif., Aug. 28, 2018 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that it has appointed Andrew Sassine as Interim Chief Financial Officer (CFO), effective August 24, 2018. Mr. Sassine has served on Arcturus’ Board of Directors sin |
|
| August 29, 2018 |
August 29, 2018 Securities and Exchange Commission 100 F Street, N.E Washington, DC 20549 Ladies and Gentlemen: We have read Form 6-K dated August 29, 2018, of Arcturus Therapeutics Ltd. and are in agreement with such statements concerning our firm. We have no basis to agree or disagree with other statements of the registrant contained therein. Very truly yours, /s/ Kost Forer Gabbay & Kasierer Ko |
|
| August 29, 2018 |
EX-99.2 3 e618248ex99-2.htm Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor San Diego, California, August 29, 2018 – Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ: ARCT), a leading RNA medicines company, today announced that at the Company’s Annual General Meeting of Shareholders on August 24, 2018, shareholders of the Compan |
|
| August 29, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) 6-K 1 e6182486k-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2018 Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, Cal |
|
| July 27, 2018 | ||
| July 27, 2018 |
APPENDIX A July 13, 2016August 24, 2018 Alcobra Ltd.Arcturus Therapeutics Ltd. (Hereinafter: the “Company”) Amended and Restated Compensation Policy for Company Office Holders (Hereinafter: the “Policy” and/or the “Compensation Policy”) 1. The Objective of the Document The objective of this document is to define and describe the Company and its subsidiaries’s Office Holder compensation policy as r |
|
| July 27, 2018 |
EX-99.1 2 e618195ex99-1.htm ARCTURUS THERAPEUTICS LTD. 10628 Science Center Drive, Suite 200, San Diego, CA 92121 Tel: (858) 900-2660 July 27, 2018 NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 24, 2018 Notice is hereby given that an Annual and Extraordinary General Meeting (the “Meeting”) of the Shareholders of Arcturus Therapeutics Ltd. (the “Company”), |
|
| July 27, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2018 (Report No. 3) Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 92 |
|
| July 27, 2018 |
APPENDIX B ARCTURUS THERAPEUTICS LTD. 2018 OMNIBUS EQUITY INCENTIVE PLAN TABLE OF CONTENTS APPENDIX B ARCTURUS THERAPEUTICS LTD. 2018 OMNIBUS EQUITY INCENTIVE PLAN TABLE OF CONTENTS PAGE Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 1 2.4 “Board” 1 2.5 “Bonus Shares” 1 2.6 “Cause” 2 2.7 “Change in Control” 2 2.8 “C |
|
| July 20, 2018 |
EX-99.1 2 e618182ex99-1.htm ARCTURUS THERAPEUTICS LTD. 10628 Science Center Drive, Suite 250, San Diego, CA 92121 Tel: (858) 900-2666 July 20, 2018 ARCTURUS THERAPEUTICS ANNOUNCES annual and EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 24, 2018 San Diego, California July 20, 2018 - Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines compan |
|
| July 20, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2018 (Report No. 2) Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 92 |
|
| July 10, 2018 |
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders All Four Proposals Approved by Shareholders San Diego, CA – July 9, 2018 – Arcturus Therapeutics Ltd. |
|
| July 10, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2018 Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 92121 (Address of |
|
| July 10, 2018 |
EX-4.14 2 arct-ex4147.htm EX-4.14 Exhibit 4.14 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 EXECUTION COPY License Agreement By and Between Protiva Biotherapeutics Inc. And Marina Biotech, Inc. TABLE OF CONTENTS Article 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 |
|
| July 10, 2018 |
Exhibit 12.4 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, K.C. Kummerfeld, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F of Arcturus Therapeutics Ltd.; and 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| July 10, 2018 |
q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) ☐ REGISTRATION STATEMENT PURSUANT TO SECTIONS 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| July 10, 2018 |
arct-ex123_8.htm Exhibit 12.3 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) |
|
| June 15, 2018 |
Fitch Proof - 92892-Arcturus Therapeutics Proxy Card Rev 08 - Front YOUR VOTE IS IMPORTANT. |
|
| June 15, 2018 |
ARCTURUS THERAPEUTICS LTD. 10628 Science Center Drive, Suite 200, San Diego, CA 92121 Tel: (858) 900-2660 June 14, 2018 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 5, 2018 Dear Arcturus Therapeutics Ltd. Shareholders: We cordially invite you to attend an Extraordinary General Meeting of Shareholders (or the Meeting), of Arcturus Therapeutics Ltd. (or the Company), to be held a |
|
| June 15, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2018 Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 92121 (Address of |
|
| June 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Arcturus Therapeutics Ltd (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) J |
|
| June 11, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 11, 2018 with respect to the Ordinary Shares, par value of NIS 0.07, of Arcturus Therapeutics Ltd., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule |
|
| May 31, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) 6-K 1 e6180656k-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2018 (Report No. 5) Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 Sa |
|
| May 31, 2018 |
Irrevocable Proxy and Power of Attorney EX-99.2 3 e618065ex99-2.htm Irrevocable Proxy and Power of Attorney The undersigned, [full name] (the “Appointer”), a shareholder in Arcturus Therapeutics Ltd, a company incorporated under the laws of the State of Israel, company number 514098995 (the “Company”), hereby provides this Irrevocable Proxy and Power of Attorney (the “Irrevocable Proxy”). The Appointer is the holder of Ordinary Shares o |
|
| May 31, 2018 |
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders EX-99.1 2 e618065ex99-1.htm Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders SAN DIEGO, May 30, 2018 (GLOBE NEWSWIRE) - Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines company, today announced that the Extraordinary General Meeting of the Shareholders of the Company that was announced on May 21, 2018 and was scheduled to be held |
|
| May 31, 2018 |
EX-99.3 4 e618065ex99-3.htm Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO Industry veteran Dr. Peter Farrell named as Chairman of the Board, Dr. Pad Chivukula reinstated as CSO and COO SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) - Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that Dr. Peter Farr |
|
| May 29, 2018 |
Exhibit 99.2 Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne SAN DIEGO, May 29, 2018 (GLOBE NEWSWIRE) - Arcturus Therapeutics Ltd. (NASDAQ:ARCT) (“Arcturus” or the “Company), a leading RNA medicines company, today announced that, as part of a settlement agreement, it has appointed four new independent directors, Dr. Peter Farrell, Mr. |
|
| May 29, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2018 (Report No. 4) Commission File No. 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 921 |
|
| May 29, 2018 |
Exhibit 99.1 AGREEMENT AND RELEASE This Agreement and Release (this “Agreement”) is made and entered into as of the Agreement Date (defined below), by and among Arcturus Therapeutics Ltd. (the “Company”), Arcturus Therapeutics, Inc., a wholly-owned subsidiary of the Company (“THI”), Stuart Collinson (“Collinson”), Craig Willett (Willett”), Daniel Geffken (“Geffken”), David Shapiro (“Shapiro”), Jos |
|
| May 24, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2018 (Report No. 3) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 921 |
|
| May 24, 2018 |
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA Exhibit 99.1 Case 3:18-cv-00766-MMA-NLS Document 40 Filed 05/22/18 PageID.855 Page 1 of 19 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA ARCTURUS THERAPEUTICS LTD., Case No.: 18cv766-MMA (NLS) Plaintiff, ORDER GRANTING IN PART AND v. DENYING IN PART PLAINTIFF'S MOTION FOR PRELIMINARY JOSEPH E. PAYNE; PETER FARRELL; INJUNCTION AND EXPEDITED ANDREW SASSINE; BRADLEY DISCOVERY SORENSON; |
|
| May 24, 2018 |
UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA EX-99.A 2 exato13da11164300305242018.htm COMPLAINT Exhibit A Case 3:18-cv-00766-MMA-NLS Document 1 Filed 04/19/18 PageID.1 Page 1 of 17 Michael L. Charlson, CA Bar No. 122125 [email protected] Mortimer H. Hartwell, CA Bar No. 154556 [email protected] VINSON & ELKINS L.L.P. 555 Mission Street, Suite 2000 San Francisco, CA 94105 Tel: (415) 979-6900 / Fax: (415) 651-8786 Ari Berman (pro hac vice |
|
| May 24, 2018 |
SC 13D/A 1 sc13da11164300305242018.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NI |
|
| May 23, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) Jeffrey Baum |
|
| May 23, 2018 |
EXHIBIT K Arcturus Therapeutics Founder Joseph Payne Calls for an End to Company’s Frivolous and Costly Lawsuits; Applauds Court Decision and Welcomes June 25, 2018 EGM Date · Applauds court decision to require disclosure of complaint filed against Joe Payne and other Arcturus shareholders as reasonable solution to end costly securities litigation · Welcomes Israeli Court order that forced Arcturus Board to set date for Extraordinary General Meeting (“EGM”) of shareholders for June 25, 2018 SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) - Joseph Payne, Founder and largest shareholder of Arcturus Therapeutics Ltd. |
|
| May 23, 2018 |
UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA Case 3:18-cv-00766-MMA-NLS Document 1 Filed 04/19/18 PageID.1 Page 1 of 17 Michael L. Charlson, CA Bar No. 122125 [email protected] Mortimer H. Hartwell, CA Bar No. 154556 [email protected] VINSON & ELKINS L.L.P. 555 Mission Street, Suite 2000 San Francisco, CA 94105 Tel: (415) 979-6900 / Fax: (415) 651-8786 Ari Berman (pro hac vice to be filed) [email protected] Lawrence S. Elbaum (pro hac vi |
|
| May 21, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2018 (Report No. 2) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 250 San Diego, California 921 |
|
| May 21, 2018 |
Exhibit 99.1 10628 Science Center Drive, Suite 250, San Diego, California 92121 Tel: (858) 900-2660 ARCTURUS THERAPEUTICS Announces EXTRAORDINARY General Meeting of Shareholders Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors San Diego, California, May 21, 2018—Arcturus Therapeutics Ltd. (Arcturus or the Company) (NASDAQ: ARCT), an RNA medicines company |
|
| May 15, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment SC 13D/A 1 e618008sc13da-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492 |
|
| May 15, 2018 |
EX-99.J 2 e618008ex-j.htm EXHIBIT J Arcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Members · Court rules that a notification for Extraordinary General Meeting must be issued this week · The Extraordinary General Meeting to be scheduled between June 18 and June 24, 2018 · Court ruling also establishes |
|
| May 14, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: May 2018 (Report No. 1) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 200 San Diego, California 921 |
|
| May 14, 2018 |
Arcturus Therapeutics Files Form 20-F EX-99.1 2 tv494141ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Arcturus Therapeutics Files Form 20-F San Diego, CA – May 14, 2018 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced the filing of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission on May 14, 201 |
|
| May 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTIONS 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC |
|
| May 14, 2018 |
Exhibit 4.14 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 EXECUTION COPY License Agreement By and Between Protiva Biotherapeutics Inc. And Marina Biotech, Inc. TABLE OF CONTENTS Article 1 DEFINITIONS AND INTERPRETATION 2 1.1 Definitions 2 1.2 Interpretation 9 Article 2 LICENSE |
|
| May 14, 2018 |
Exhibit 4.13 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT between CUREVAC and ARCTURUS Confidential Execution Copy CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT This CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT (this “ |
|
| May 14, 2018 |
Exhibit 4.6 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 4th day of October, 2017, between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Building: 10628 Science Center Drive, San Diego, California Premises: That portion of the Project, containing approximately 24,705 rentable squ |
|
| May 14, 2018 |
Exhibit 4.11 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 CFFT FINAL 5/16/17 May 16, 2017 Padmanabh Chivukula, PhD Arcturus Therapeutics, Inc. 10628 Science Center Dr., Suite 200 San Diego, CA 92121 Development Program: Nebulized LUNAR-formulated CFTR mRNA Amount of Award: $3, |
|
| May 14, 2018 |
Exhibit 4.12 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 Execution Copy Development and Option Agreement by and between CureVac AG and Arcturus Therapeutics Inc. dated 1 January 2018 Development and Option Agreement between CureVac AG and Arcturus Therapeutics Inc Table of Co |
|
| May 14, 2018 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form F-3 (Registration No. 333-209960) and Registration Statements on Form S-8 (Registration No’s. 333-194875, 333-202394, 333-209947, 333-217556, and 333-221830) of Arcturus Therapeutics Ltd. (formerly Alcobra Ltd.) of our report dated May 14, 2018 with resp |
|
| May 14, 2018 |
Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350. Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2017 (the “Report”) by Arcturus Ltd. (the "Company"), the undersigned, as Vice President, Finance & Operations of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act |
|
| May 14, 2018 |
Consent of Kost, Forer, Gabbay & Kasierer. Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form F-3 (Registration No. 333-209960) and Registration Statements on Form S-8 (Registration No’s. 333-194875, 333-202394, 333-209947 333-217556, and 333-221830) of Arcturus Therapeutics Ltd. of our report dated May 14, 2018 with respect to the consolidated f |
|
| May 14, 2018 |
Exhibit 3.1 VOTING TRUST AGREEMENT This Voting Trust Agreement (this “Agreement”) is made and entered into effective for all purposes and in all respects as of February 11, 2018 by and among (i) Arcturus Therapeutics Ltd., an Israeli company, or its successors and assigns (the “Company”), (ii) Padmanabh Chivukula (the “Shareholder”), and (iii) the then-acting Principal Executive Officer (defined b |
|
| May 14, 2018 |
Exhibit 4.8 CONFIDENTIAL ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 Research and exclusive LICENSE AGREEMENT This Research and Exclusive License Agreement (“Agreement”) is entered into by and between Arcturus Therapeutics, Inc., a Delaware corporation (“Arcturus”), and Synth |
|
| May 14, 2018 |
Exhibit 4.10 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 Confidential RESEARCH COLLABORATION AND LICENSE AGREEMENT This Research Collaboration and License Agreement (this “Agreement”) is entered into as of October 26, 2015 (the “Effective Date”) by and between Ultragenyx Phar |
|
| May 14, 2018 |
Exhibit 4.9 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 COVERSHEET RESEARCH AGREEMENT Arcturus Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, USA and having its registered office at 10628 Science Center Drive Suite 200, San Diego, Califor |
|
| May 14, 2018 |
Exhibit 4.7 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 RESEARCH COLLABORATION AND LICENSE AGREEMENT Between Arcturus Therapeutics, Inc. And Janssen Pharmaceuticals, Inc. i EXECUTION COPY INDEX OF DEFINITIONS ADT 35 FTE Rate 39 Affiliate 34 GLP 40 After-Acquire |
|
| May 14, 2018 |
Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Mark R. Herbert, certify that: 1. I have reviewed this annual report on Form 20–F of Arcturus Therapeutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| May 14, 2018 |
Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350. Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2017 (the “Report”) by Arcturus Therapeutics Ltd. (the "Company"), the undersigned, as Interim President of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 20 |
|
| May 14, 2018 |
Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Rebecque Laba, certify that: 1. I have reviewed this annual report on Form 20–F of Arcturus Therapeutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances un |
|
| May 14, 2018 |
Exhibit 4.15 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 Patent assignment and license agreement By and Between Arcturus therapeutics, inc. And Marina biotech, inc. This PATENT ASSIGNMENT AND LICENSE AGREEMENT, dated August 9, 2013 (“Effective Date”), is entered into by and b |
|
| May 14, 2018 |
Letter dated May14, 2018 of Ernst & Young LLP, as required by Item 16F of Form 20-F. Exhibit 15.3 Ernst & Young LLP 4370 La Jolla Village Drive Suite 500 San Diego, CA 92122 Tel: +(858) 535 7200 Fax: +(858) 535 7777 ey.com May 14, 2018 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 16F of Form 20-F dated May 14, 2018, of Arcturus Therapeutics Ltd. and are in agreement with the statements contained in the first and |
|
| May 2, 2018 |
EX-99.I 2 e617964ex-i.htm EXHIBIT I Arcturus Therapeutics Founder Joseph Payne Successfully Prevents Board’s Egregious Attempt to Dilute Shareholders · Israeli District Court enjoins attempt by board to dilute shareholders through sale of 24.9% of Arcturus share capital · Court found sufficient evidence to support the claim that the members of the Arcturus board are motivated by their own self-int |
|
| May 2, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) Jeffrey Baum |
|
| April 30, 2018 |
SC 13D 1 sc13d1124700204302018.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class o |
|
| April 30, 2018 |
EX-99.1 2 ex991to13d1124700204302018.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Ordinary Shares, par value NIS 0.07, |
|
| April 27, 2018 |
ADHD / Alcobra Ltd. FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL FORM 12b-25 OMB Number:…….3235-0058 Expires: October 31, 2018 NOTIFICATION OF LATE FILING Estimated average burden hours per response..........2.50 SEC FILE NUMBER 001-35932 CUSIP NUMBER (Check one): ¨ Form10 K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, |
|
| April 23, 2018 |
EXHIBIT H Arcturus Therapeutics Founder Joseph Payne Dismisses Board’s Baseless Lawsuit as Desperate Entrenchment Tactic · Warns lawsuit is another attempt by Arcturus’ board to distract shareholders from the Company’s abhorrent governance deficiencies · Calls on board to respect the rights of all shareholders and immediately set date for Extraordinary General Meeting SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) - Joseph Payne, Founder and largest shareholder of Arcturus Therapeutics Ltd. |
|
| April 23, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment SC 13D/A 1 e617939sc13da-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492 |
|
| April 19, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment SC 13D/A 1 e617924sc13da-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492 |
|
| April 19, 2018 |
EXHIBIT G April 18, 2018 To: The Board of Directors Arcturus Therapeutics Ltd. do Meitar Liquomik Geva Leshem Tal [email protected] 16 Abba Hillel Road, 12th Floor Ramat Gan 5250608 [email protected] 10628 Science Center Drive San Diego CA 92121 U.S.A. By Email and Courier Re: Restated Demand to Convene an Extraordinary General Meeting Dear Sirs, 1. By letter dated February 12, 2018[1] and a |
|
| April 13, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) Jeffrey Baum |
|
| April 13, 2018 |
EX-99.F 2 e617906ex-f.htm EXHIBIT F Arcturus Therapeutics Founder Joseph Payne Disappointed by Board’s Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability · Change in Arcturus board is needed on an urgent basis to improve the company’s performance · Board’s decision to indefinitely delay inevitable change is a clear act of entrenchment · Overwhelming support for Mr. Payne’s nom |
|
| April 9, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 2018 (Report No. 2) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 200 San Diego, California 9 |
|
| April 9, 2018 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders Postponement due to Joseph Payne’s Focus on Advancing His Personal Agenda at the Expense of Arcturus Shareholders San Diego, CA – April 8, 2018 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that upon the recommen |
|
| April 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) |
|
| April 9, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated April 9, 2018 with respect to the Ordinary Shares, par value of NIS 0.07, of Arcturus Therapeutics Ltd., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule |
|
| April 4, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment SC 13D/A 1 e617877sc13da-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492 |
|
| April 4, 2018 |
EX-99.E 2 e617877ex-e.htm EXHIBIT E April 3, 2018 To: Arcturus Therapeutics Ltd. Stuart Collinson, Executive Chairman of the Board Craig Willett, Director Daniel Geffken, Director David Shapiro, Director 10628 Science Center Drive San Diego, CA 92121 I founded Arcturus Therapeutics in 2013 to discover novel RNA therapeutics for diseases for which there is no adequate treatment. Through all of this |
|
| April 2, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: April 2018 (Report No. 1) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 200 San Diego, California 9 |
|
| April 2, 2018 |
To: Arcturus Therapeutics Ltd. Employees Exhibit 99.1 To: Arcturus Therapeutics Ltd. Employees From: Mark Herbert, Interim President Date: April 2, 2018 Subject: Notes from the Road Hi Team, We are excited to share some of the great progress we have been making at Arcturus across our ongoing preclinical programs and collaborations. We are confident that we are well-positioned to deliver on our objective of developing innovative RNA medic |
|
| March 28, 2018 |
Exhibit 99.1 Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders Complaint Details Extensive Misconduct by Mr. Payne during Tenure as CEO Cites Mr. Payne’s Self-Dealing and Inappropriate Business Conflicts of Interest San Diego, CA – March 27, 2018 – Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today initi |
|
| March 28, 2018 |
EX-99.2 3 tv489828ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Arcturus Therapeutics Issues Open Letter to Shareholders Details Former President and CEO Joseph E. Payne’s Poor Judgment, Failed Leadership and Deceit that Led to His Termination for Cause Cites Payne’s Self-Dealing and Blatant Disloyalty to Arcturus, its Shareholders and Collaborators San Diego, CA – March 28, 2018 – Arcturus Therapeutics Lt |
|
| March 28, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2018 (Report No. 2) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 200 San Diego, California 9 |
|
| March 12, 2018 |
Exhibit 99.1 10628 Science Center Drive, Suite 200, San Diego, California 92121 Tel: (858) 900-2660 ARCTURUS THERAPEUTICS Announces EXTRAORDINARY General Meeting of Shareholders Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors San Diego, California, March 11, 2018—Arcturus Therapeutics Ltd. (Arcturus or the Company) (NASDAQ: ARCT), an RNA medicines compa |
|
| March 12, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: March 2018 (Report No. 1) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant’s name into English) 10628 Science Center Drive, Suite 200 San Diego, California 9 |
|
| February 28, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: February 2018 (Report No. 4) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant?s name into English) 10628 Science Center Drive, Suite 200 San Diego, Californi |
|
| February 22, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Chivukula Pad - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 22, 2018 |
EX-99.1 2 tv486660ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT We, the signatories of the statement on Schedule 13D to which this Agreement is attached, hereby agree that such statement is, and any amendments thereto filed by any of us will be, filed and on behalf of each of us. Date: February 22, 2018 /s/ Padmanabh Chivukula Padmanabh Chivukula /s/ Mark Herbert Mark Herbert |
|
| February 22, 2018 |
EX-99.4 3 tv486660ex99-4.htm EXHIBIT 99.4 EXHIBIT 99.4 VOTING TRUST AGREEMENT This Voting Trust Agreement (this “Agreement”) is made and entered into effective for all purposes and in all respects as of February 11, 2018 by and among (i) Arcturus Therapeutics Ltd., an Israeli company, or its successors and assigns (the “Company”), (ii) Padmanabh Chivukula (the “Shareholder”), and (iii) the then-ac |
|
| February 13, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: February 2018 (Report No. 3) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant?s name into English) 10628 Science Center Drive, Suite 200 San Diego, Californi |
|
| February 13, 2018 |
February 12, 2018 To: The Board of Directors Arcturus Therapeutics Ltd. c/o Meitar Liquornik Geva Leshem Tal [email protected] [email protected] 10628 Science Center Drive, Suite 200 16 Abba Hillel Road, 12th Floor San Diego CA 92121 Ramat Gan 5250608 U.S.A. By Email and Courier Re: Demand to Convene an Extraordinary General Meeting Dear Sirs, 1. The undersigned, Mr. Joseph E. Payne, is the |
|
| February 13, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 (CUSIP Number) Jeffrey Baum |
|
| February 13, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Baker Brothers Advisors LP - AMENDMENT NO. 1 Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 7, 2018 |
EX-99.1 2 tv485110ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT We, the signatories of the statement on Schedule 13D to which this Agreement is attached, hereby agree that such statement is, and any amendments thereto filed by any of us will be, filed and on behalf of each of us. Date: February 7, 2018 /S/ Craig Willett Craig Willett Phoenician Enterprises, Ltd. By: /S/ Craig Willett |
|
| February 7, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Willett Craig - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2018 |
BARN EA Without Prejudice By email Re: Arcturus Therapeutics Ltd. Dear Sirs, This letter is sent to you on behalf of our client, Mr. Joseph Payne, a shareholder, a member of the board of directors (the "Board") and the President and Chief Executive Officer (the "Position") of Arcturus Therapeutics Ltd. (formerly, Alcobra Ltd), Israeli company number 514098995 (the "Company"). Our client is also on |
|
| February 6, 2018 |
ARCTURUS THERAPEUTICS, INC. COMMON STOCK PURCHASE AGREEMENT ARCTURUS THERAPEUTICS, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is made as of March 4, 2013 by and between Arcturus Therapeutics, Inc., a Delaware corporation (the “Company”), and Joseph E. Payne (“Purchaser”). 1. Sale of Stock. Subject to the terms and conditions of this Agreement, simultaneously with the execution and delivery of this Agreement |
|
| February 6, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Payne Joseph E Activist Investment SC 13D 1 e617632sc13d-at.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )* Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.07 (Title of Class of Securities) M1492T105 |
|
| February 6, 2018 |
Lock-Up Agreement September 27, 2017 EX-99.C 4 e617632ex99-c.htm Lock-Up Agreement September 27, 2017 Ladies and Gentlemen: The undersigned (the “Shareholder”) understands that: (i) Alcobra Ltd., an Israeli company (“Alcobra”), has entered into an Agreement and Plan of Merger and Reorganization, dated as of September 27, 2017 (the “Merger Agreement”), with Arcturus Therapeutics, Inc., a Delaware corporation (“Arcturus”) and Aleph Mer |
|
| February 5, 2018 |
Exhibit 99.2 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUICK *** EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail ARCTURUS THERAPEUTICS LTD. Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern |
|
| February 5, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: February 2018 (Report No. 2) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant?s name into English) 10628 Science Center Drive, Suite 200 San Diego, Californi |
|
| February 5, 2018 |
Exhibit 99.1 ARCTURUS THERAPEUTICS LTD. 10628 Science Center Drive, Suite 200, San Diego, CA 92121 Tel: (858) 900-2660 February 5, 2018 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 26, 2018 Dear Arcturus Therapeutics Ltd. Shareholders: We cordially invite you to attend an Extraordinary General Meeting of Shareholders, or the Meeting, of Arcturus Therapeutics Ltd., or the Co |
|
| February 2, 2018 |
ADHD / Alcobra Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: February 2018 (Report No. 1) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant?s name into English) 10628 Science Center Drive, Suite 200 San Diego, Californi |
|
| January 30, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of: January 2018 (Report No. 2) Commission File Number 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of Registrant?s name into English) 10628 Science Center Drive, Suite 200 San Diego, California |
|
| January 30, 2018 |
Exhibit 99.1 10628 Science Center Drive, Suite 200, San Diego, California 92121 Tel: (858) 900-2660 ARCTURUS THERAPEUTICS Announces EXTRAORDINARY General Meeting of Shareholders San Diego, California, January 30, 2018?Arcturus Therapeutics Ltd., or Arcturus (NASDAQ: ARCT), an RNA medicines company, today announced that it will hold an extraordinary general meeting of shareholders on Monday, Februa |
|
| January 24, 2018 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2018 (Report No. 1) Commission file number: 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant?s name into English) 10628 Science Center Drive, Suite 200 San Diego, Califo |
|
| January 19, 2018 |
ARCT / Arcturus Therapeutics Ltd. / Sorenson Bradley T. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title of Class of Securities) M1492T105 (CUSIP Number) bradley thoma |
|
| January 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 10)1 Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title of Class of Securities) M1492T105 (CUSIP Number) Amir Efrati |
|
| December 11, 2017 |
ARCT / Arcturus Therapeutics Ltd. / FRANKLIN RESOURCES INC Passive Investment arct17a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. M1492T105 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARCTURUS THERAPEUTICS LTD. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M1492T105 (CUSIP Number) November 30, 2 |
|
| November 30, 2017 |
Arcturus Therapeutics, Inc. 2013 Equity Incentive Plan EX-99.1 5 tv480453ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2013 EQUITY INCENTIVE PLAN OF ARCTURUS THERAPEUTICS, INC. Adopted June 26, 2013 TABLE OF CONTENTS Page 1. GENERAL 1 2. DEFINITIONS 1 3. ADMINISTRATION 5 4. SHARES SUBJECT TO THE PLAN 7 5. ELIGIBILITY 8 6. OPTION AGREEMENT PROVISIONS 8 7. PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS 12 8. COVENANTS OF THE COMPANY 13 9. USE OF PROCEEDS 13 10. A |
|
| November 30, 2017 |
EX-4.1 2 tv480453ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Articles of Association of Arcturus Therapeutics Ltd. A Company Limited by Shares Under The Companies Law, 5759-1999 Chapter 1 General 1 Chapter 2 Shares and Share Capital 2 Chapter 3 General Meetings 5 Chapter 4 The Board of Directors 7 Chapter 5 Committees of the Board of Directors 10 Chapter 6 General Manager 11 Chapter 7 Exemption, Insurance, |
|
| November 30, 2017 |
As filed with the Securities and Exchange Commission on November 30, 2017 Registration No. |
|
| November 20, 2017 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Ordinary Shares, par value of NIS 0.01, of Arcturus Therapeutics Ltd., an Israeli corporation. This |
|
| November 20, 2017 |
SC 13D/A 1 sc13da91124700211202017.htm AMENDMENT NO. 9 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)1 Arcturus Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value of NI |
|
| November 16, 2017 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4797266k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2017 (Report No. 4) Commission file number: 001-35932 ARCTURUS THERAPEUTICS LTD. (Translation of registrant’s name into English) 10628 Science Center Dri |
|
| November 16, 2017 |
Exhibit 99.1 Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market ? Combined Company Commences Trading on the Nasdaq Global Market on November 16, 2017 under the Ticker Symbol ?ARCT? ? Approximately $50.1 Million in Net Cash Following Closing of the Merger ? Ten (10) Pipeline Programs, Six (6) of Which Are Externally Funded by Pha |
|
| November 13, 2017 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2017 (Report No. 3) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel A |
|
| November 9, 2017 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) 6-K 1 tv4790676k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant’s name into English) Azrieli Triangle Building 132 Derech M |
|
| November 9, 2017 |
ALCOBRA ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 Investor Contacts Alcobra Investor Relations [email protected] ALCOBRA ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Tel Aviv, Israel ? November 9, 2017 ? Alcobra Ltd. (NasdaqGM: ADHD) today announced financial results for the three and nine months ended September 30, 2017, and provided a corporate update. Third Quarter and Recent Corporate Updates: |
|
| November 7, 2017 |
ADHD / Alcobra Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Isr |
|
| October 20, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Av |
|
| October 20, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Isra |
|
| October 20, 2017 |
ALCOBRA LTD. AMENDED NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 ALCOBRA LTD. AMENDED NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Background On October 28, 2017, Alcobra Ltd. (the “Company”) furnished to the Securities and Exchange Commission (“SEC”) a notice of extraordinary general meeting of shareholders (the “Original Notice”). This amended notice of extraordinary general meeting of shareholders amended and restates the Original Not |
|
| October 20, 2017 |
ALCOBRA LTD. TEL AVIV, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.2 ALCOBRA LTD. TEL AVIV, ISRAEL PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is furnished to the holders of ordinary shares, NIS 0.01 par value per share (?Ordinary Shares?), of Alcobra Ltd. (?Alcobra? or the ?Company?) in connection with the solicitation by the Board of Directors of Alcobra (the ?Board?) of proxies for use at Alcobra?s Extraordinar |
|
| October 20, 2017 |
Fitch Proof 90719_CST_Alcobra_Proxy Card Front Exhibit 99.3 Fitch Proof 90719CSTAlcobraProxy Card Front YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. 2017 Extraordinary General Meeting of Shareholders of Alcobra Ltd. November 2, 2017, 10:00 am Israel time This Proxy is Solicited On Behalf Of The Board Of Directors PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. Please mark your votes like this X PROXY To approve certain resolution |
|
| September 28, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2017 (Report No. 3) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel |
|
| September 28, 2017 |
ALCOBRA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 ALCOBRA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of the Shareholders of Alcobra Ltd. (the ?Company?) will be held on November 2, 2017, at 10:00 am (Israel Time), at the offices of the Company?s counsel (Zysman, Aharoni, Gayer & Co.) at ?Beit Zion?, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv 6578401, Israel |
|
| September 28, 2017 |
Exhibit 99.2 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among ALCOBRA LTD. an Israeli company; ALEPH MERGERSUB, INC., and ARCTURUS THERAPEUTICS, INC. Dated as of September 27, 2017 Table of Contents Page Article 1 DESCRIPTION OF TRANSACTION 3 1.1 Structure of the Merger 3 1.2 Effects of the Merger 3 1.3 Closing; Effective Time 3 1.4 Certificate of Incorporation and Bylaws; Directors and Offic |
|
| September 28, 2017 |
Arcturus Therapeutics / Alcobra Merger Enabling a New Era of RNA Medicines September 28, 2017 Exhibit 99.3 Arcturus Therapeutics / Alcobra Merger Enabling a New Era of RNA Medicines September 28, 2017 Forward Looking Statements This presentation contains forward - looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially diffe ren t from a |
|
| September 28, 2017 |
Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge Exhibit 99.1 Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge ? Transaction to result in NASDAQ-listed company focused on developing novel RNA medicines and technologies ? Arcturus brings a proprietary and diverse pipeline with seven programs, four of which are funded by pharmaceutical and strategic partners ? Plan to accelerate development of internal programs targeting rare diseases ? |
|
| September 28, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant?s name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel |
|
| September 14, 2017 |
ALCOBRA LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 ALCOBRA LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual and Extraordinary General Meeting of the Shareholders of Alcobra Ltd. (?Alcobra?) will be held on October 19, 2017, at 10:00 am (Israel Time), at the offices of Alcobra?s counsel (Zysman, Aharoni, Gayer & Co.) at ?Beit Zion?, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv 6 |
|
| September 14, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant?s name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Is |
|
| August 11, 2017 |
ALCOBRA ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 Investor Contacts Alcobra Investor Relations [email protected] ALCOBRA ANNOUNCES SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Tel Aviv, Israel ? August 11, 2017 ? Alcobra Ltd. (NasdaqGM: ADHD) today announced financial results for the three and six months ended June 30, 2017, and provided a corporate update. Second Quarter and Recent Corporate Updates: ? On |
|
| August 11, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4730296k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant’s name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th |
|
| July 3, 2017 |
Irrevocable Resignation Letter EX-99.1 2 ex991to13da811247002062917.htm COOPERATION AGREEMENT Exhibit 99.1 June 12, 2017 Reference is made to: (i) the agreement (the “Settlement Agreement”) between Alcobra Ltd. (the “Company”) and Brosh Capital Partners L.P. (formerly named Exodus Capital L.P.), Brosh Capital L.P., Amir Efrati and Asaf Frumerman, of May 5, 2017, which was also approved by the Economic Division of the District C |
|
| July 3, 2017 |
SC 13D/A 1 sc13da81124700206292017.htm AMENDMENT NO. 8 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title |
|
| June 23, 2017 |
Alcobra 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant?s name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv |
|
| June 23, 2017 |
Alcobra Updates on its Review of Strategic Alternatives EX-99.1 2 v469537ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alcobra Updates on its Review of Strategic Alternatives TEL AVIV, Israel, June 23, 2017 - Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that its Board of Directors is conducting a process to explore and review a range of st |
|
| June 12, 2017 |
Irrevocable Resignation Letter Exhibit 99.2 June 12, 2017 Reference is made to: (i) the agreement (the ?Settlement Agreement?) between Alcobra Ltd. (the ?Company?) and Brosh Capital Partners L.P. (formerly named Exodus Capital L.P.), Brosh Capital L.P., Amir Efrati and Asaf Frumerman, of May 5, 2017, which was also approved by the Economic Division of the District Court of Tel Aviv (the ?Court?), and (ii) the letter from Brosh |
|
| June 12, 2017 |
Exhibit 99.1 Alcobra Announces Cooperation Agreement with Brosh Group and Board Additions Company Adds Two Directors to the Board Company to Continue Strategic Alternatives Process to Maximize Value for All Shareholders TEL AVIV, Israel, June 12, 2017 - Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical |
|
| June 12, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4688176k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th F |
|
| May 30, 2017 |
ALCOBRA ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 Investor Contacts Alcobra Investor Relations [email protected] ALCOBRA ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Tel Aviv, Israel – May 30, 2017 – Alcobra Ltd. (NasdaqGM: ADHD) today announced financial results for the three months ended March 31, 2017, and provided a corporate update. First Quarter and Recent Corporate Updates: · Alcobra recentl |
|
| May 30, 2017 |
Alcobra 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2017 (Report No. 3) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6 |
|
| May 15, 2017 |
EX-99.1 2 v467020ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Alcobra Announces Leadership Update Dr. Yaron Daniely to Step Down as Chief Executive Officer, Effective May 31, 2017 David Baker Named Interim Chief Executive Officer Dr. Daniely to Remain on Board of Directors and be Appointed Chairman TEL AVIV, Israel, May 15, 2017 - Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on |
|
| May 15, 2017 |
Alcobra 6-K (Current Report of Foreign Issuer) 6-K 1 v4670206k.htm 6-K REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant’s name into English) Azrieli Triangle |
|
| May 9, 2017 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Ordinary Shares, par value of NIS 0.01, of Alcobra Ltd. This Joint Filing Agreement shall be filed a |
|
| May 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title of Class of Securities) M2239P 10 9 (CUSIP Number) Amir Efrati Brosh Capita |
|
| May 5, 2017 |
Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group Exhibit 99.1 Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group TEL AVIV, Israel, May 5, 2017 ? Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that it has reached an agreement (the ?Agreement") with Brosh Capital L.P. and certain of its affil |
|
| May 5, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4662706k.htm FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant’s name into English) Azrieli Triangle Building |
|
| April 28, 2017 |
S-8 1 v465188s8.htm FORM S-8 As filed with the Securities and Exchange Commission on April 28, 2017 Registration No. 333- United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 alcobra ltd. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organiza |
|
| April 28, 2017 |
20-F 1 v46395520f.htm 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number: 001-35932 Alcobra Ltd. (Exact name of Registrant as specified in its charter) State of Israel (Jurisdiction of incorporation or organizati |
|
| April 27, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4653776k.htm FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2017 (Report No. 3) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant’s name into English) Azrieli T |
|
| April 24, 2017 |
Exhibit 99.1 ALCOBRA LTD. TEL-AVIV, ISRAEL Dear Shareholder: Brosh Capital L.P., Exodus Capital L.P., Exodus Management Israel Ltd. and Amir Efrati (together, the ?Brosh Group?) have called an extraordinary general meeting of shareholders (the ?Extraordinary General Meeting?) of Alcobra Ltd. (the ?Company? or ?Alcobra?) seeking among other things to remove and replace the entire Board of Directors |
|
| April 24, 2017 |
Alcobra REPORT OF FOREIGN PRIVATE ISSUER (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant?s name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv |
|
| April 24, 2017 |
Exhibit 99.2 Alcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders The Board Will Defend Shareholders from Opportunistic Takeover of the Company Believes Brosh Capital’s Request Does Not Comply With Alcobra’s Articles of Association TEL AVIV, Israel, April 24, 2017 - Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medicatio |
|
| April 12, 2017 |
SC 13D/A 1 sc13da61124700204112017.htm AMENDMENT NO. 6 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title |
|
| April 12, 2017 |
Exhibit 99.1 April 12, 2017 To: Alcobra Ltd ("The Company") 132 Derech Menachem Begin Tel-Aviv 6701101 Brosh Capital is summoning an Extraordinary General Meeting [References: Brosh Capital LP and Exodus Capital LP letter dated Marth 16th, 2017 (the "Request Letter") and The Company's letter dated April 5th, 2017 ("Response Letter")] We hereby confirm receipt of your letter dated April 5th, 2017, |
|
| April 12, 2017 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALCOBRA LTD. Exhibit 99.2 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALCOBRA LTD. On March 16th, 2017 Brosh Capital L.P. and Exodus Capital L.P., (shareholders holding approximately 17% of the voting rights in the Company) ("The Shareholders"), requested Alcobra Ltd's. (“Company”) board of directors to convene an extraordinary meeting of the shareholders of the Company, in accordance with secti |
|
| April 10, 2017 |
Alcobra AMENDMENT NO. 5 TO THE SCHEDULE 13D (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 5)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title of Class of Securities) M2239P 10 9 (CUSIP Number) Amir Efrati Exodus Capit |
|
| April 5, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Israel |
|
| April 5, 2017 |
Exhibit 99.1 Alcobra Provides Update on Request for Extraordinary General Meeting Brosh Capital?s Request Does Not Comply With Alcobra?s Articles of Association Company Addresses Brosh Capital?s Misinformed Views TEL AVIV, Israel ? April 5, 2017 ? Alcobra Ltd. (Nasdaq: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat CNS and cognitive disorders, toda |
|
| April 4, 2017 |
EX-99.1 2 ex991to13da411247002040417.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Ordinary Shares, par value of NIS 0. |
|
| April 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title of Class of Securities) M2239P 10 9 (CUSIP Number) Amir Efrati Exodus Capit |
|
| March 27, 2017 |
SC 13D/A 1 sc13da31124700203272017.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title |
|
| March 16, 2017 |
SC 13D/A 1 sc13da21124700203162017.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title |
|
| March 16, 2017 |
BROSH CAPITAL L.P. 11 Menachem Begin Rd. Ramat-Gan, Israel 5268104 Exhibit 99.1 BROSH CAPITAL L.P. 11 Menachem Begin Rd. Ramat-Gan, Israel 5268104 [email protected] March 16, 2017 Alcobra Ltd. Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Israel Attn: Howard B. Rosen, Chairman of the Board of Directors Dear Mr. Rosen, Brosh Capital L.P., together with its affiliates (collectively, “Brosh”), are the beneficial owners of appr |
|
| February 24, 2017 |
SC 13D/A 1 sc13da11124700202242017.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title |
|
| February 15, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4597066k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Me |
|
| February 15, 2017 |
ALCOBRA ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-390-8964, Intl: +972-3-7299871 [email protected] ALCOBRA ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Conference Call & Webcast February 15th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time Tel Aviv, Israel ? February 15, 2017 ? Alcobra Ltd. (NasdaqGM: ADHD), an emergin |
|
| February 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALCOBRA LTD. (Name of Issuer) ORDINARY SHARES (Title of Class of Securities) M2239P109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 14, 2017 |
Alcobra 3G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 c8742413ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934* Alcobra Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M2239P109 (CINS Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2017 |
Alcobra FEBRUARY 14, 2017 (Passive Acquisition of More Than 5% of Shares) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2 )* Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value NIS $0.01 per share (Title of Class of Securities) M2239P109 (CUSIP Number) December 31, 2016 (Date of E |
|
| February 14, 2017 |
ARCT / Arcturus Therapeutics Ltd. / Knoll Capital Management, LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Alcobra Ltd, (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) M2239P109 (CUSIP Number) December 31, 2 |
|
| February 13, 2017 |
ARCT / Arcturus Therapeutics Ltd. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 6, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant’s name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Isr |
|
| February 6, 2017 |
Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD Exhibit 99.1 Alcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD ? Pre-IND meeting held on Alcobra?s proprietary Abuse-Deterrent, Amphetamine Immediate Release (ADAIR) product candidate. ? Meeting defined a 505(b)(2) development path, to be funded with existing cash balance, and targeting a 2H 2018 NDA submission ? Investor call to be held on February 7, 2017 at 8:30 |
|
| February 2, 2017 |
EX-99.1 2 e615710ex99-1.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Ordinary Shares, par value of NIS 0.01, of Alcobr |
|
| February 2, 2017 |
ARCT / Arcturus Therapeutics Ltd. / Brosh Capital L.P. - THE SCHEDULE 13D Activist Investment SC 13D 1 e615710sc13d-alcobra.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value of NIS 0.01 (Title of Class of Securities) M |
|
| January 17, 2017 |
Alcobra 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2017 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Av |
|
| January 17, 2017 |
Exhibit 99.1 Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-8908964, Intl: +972-3-7299871 [email protected] Alcobra Reports Phase 3 Clinical Trial of MDX in Adults with ADHD Missed Primary Endpoint - Management to hold a conference call & webcast today, January 17th at 8:00 a.m. EST Tel Aviv, Israel ? January 17, 2017 ? Alcobra Ltd. (NasdaqGM: ADHD), an emerging pharmaceutica |
|
| January 9, 2017 |
Exhibit 99.1 Investor Contacts Alcobra Investor Relations Debbie Kaye US: 212-8908964, Intl: +972-3-7299871 [email protected] Alcobra Provides Update on Recent FDA Meeting and Path Forward for MDX Clinical Development Program - Alcobra and FDA agree on review of available data from the Phase 3 MEASURE study in a future NDA submission - Top-line results from the MEASURE study to be reported in |
|
| January 9, 2017 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2017 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Isra |
|
| November 15, 2016 |
ALCOBRA ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 U.S. Investor Contacts Media Inquiries Israel Investor Contact: LifeSci Advisors, LLC Sam Brown, Inc. Alcobra Investor Relations Michael Rice Mike Beyer Debbie Kaye 646-597-6979 312-961-2502 +972-72 2204661 [email protected] [email protected] [email protected] ALCOBRA ANNOUNCES THIRD QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ? Conference Call & |
|
| November 15, 2016 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2016 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Isr |
|
| November 9, 2016 |
Alcobra 3G/A (Passive Acquisition of More Than 5% of Shares) alco16a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. M2239P109 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alcobra Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M2239P109 (CUSIP Number) October 31, 2016 (Date of Ev |
|
| October 21, 2016 |
Alcobra SC 13G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALCOBRA LTD. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M2239P109 (CUSIP Number) October 13, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| October 7, 2016 |
Update from Alcobra on Recent FDA Communications Exhibit 99.1 U.S. Investor Contacts Media Inquiries Israel Investor Contact: LifeSci Advisors, LLC Sam Brown, Inc. Alcobra Investor Relations Michael Rice Mike Beyer Debbie Kaye 646-597-6979 773-463-4211 +972-72 2204661 [email protected] [email protected] [email protected] Update from Alcobra on Recent FDA Communications Tel Aviv, Israel ? October 7, 2016 ? Alcobra Ltd. (Nasda |
|
| October 7, 2016 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2016 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Isra |
|
| September 29, 2016 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2016 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Is |
|
| September 29, 2016 |
Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study Exhibit 99.1 U.S. Investor Contacts Media Inquiries Israel Investor Contact: LifeSci Advisors, LLC Sam Brown, Inc. Alcobra Investor Relations Michael Rice Mike Beyer Debbie Kaye 646-597-6979 773-463-4211 +972-72 2204661 [email protected] [email protected] [email protected] Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study Tel Aviv, Israel ? Septembe |
|
| August 30, 2016 |
Exhibit 99.1 U.S. Investor Contacts Media Inquiries Israel Investor Contact: LifeSci Advisors, LLC Sam Brown, Inc. Alcobra Investor Relations Michael Rice Mike Beyer Debbie Kaye 646-597-6979 773-463-4211 +972-72 2204661 [email protected] [email protected] [email protected] ALCOBRA ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ? Conference Call & |
|
| August 30, 2016 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2016 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv 6701101 Israe |
|
| July 19, 2016 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2016 (Report No. 2) Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel Aviv |
|
| July 19, 2016 |
Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome Exhibit 99.1 U.S. Investor Contacts Media Inquiries Israel Investor Contact: LifeSci Advisors, LLC Sam Brown, Inc. Alcobra Investor Relations Michael Rice Mike Beyer Debbie Kaye 646-597-6979 312-961-2502 +972-72 2204661 [email protected] [email protected] [email protected] Alcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome Tel Aviv, Israel ? |
|
| July 19, 2016 |
Alcobra FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4444826k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2016 Commission file number: 001-35932 ALCOBRA LTD. (Translation of registrant's name into English) Azrieli Triangle Building 132 Derech Menachem Begin 39th F |
|
| June 8, 2016 |
ALCOBRA LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 ALCOBRA LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of the Shareholders of Alcobra Ltd. (?Company?) will be held on July 19, 2016, at 10:00 am (Israel Time), at the offices of the Company's counsel (Zysman, Aharoni, Gayer & Co.) at "Beit Zion", 41-45 Rothschild Blvd., 8th Fl., Tel Aviv 6578401, Israel (?Meeting?), for the |
